About Semax - Memory Neuro Support Peptide

Semax is a nootropic peptide that ramps up BDNF (brain-derived neurotrophic factor) to support neuroplasticity, memory retention, and overall brain health. It delivers clean, stimulant-free mental drive, sharp focus, and mental clarity without the jitters or an energy crash. WHAT THE RESEARCH SHOWS Research on Semax, a synthetic analogue of an ACTH fragment (ACTH 4-10) highlights it as one of the most potent cognitive-enhancing and neuroprotective peptides available.
Here is what the clinical and preclinical studies show:
* Surges BDNF and NGF: Research shows Semax rapidly triggers a massive spike in Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the hippocampus. This enhances neuroplasticity, memory encoding, and cellular repair.
* Executive Function & Focus: It modulates dopamine and serotonin turnover, significantly improving attention span, working memory, and mental clarity. It is frequently studied as a non-stimulant alternative for ADHD symptoms and deep cognitive fatigue.
* Neuroprotection & Stroke Recovery: Originally developed and clinically approved in Russia,
Semax is heavily researched for protecting brain tissue against ischemic stroke, traumatic brain injuries (TBI), and hypoxic stress by suppressing neuroinflammation and oxidative damage.
* Clean Mental Energy: Unlike pharmaceutical stimulants (like Adderall or modafinil), research notes it sharpens focus and stamina without causing heart palpitations, anxiety spikes, or an energy crash. While Selank is more about calming anxiety and smoothing out stress, Semax is strictly about mental drive, learning capacity, and sharp focus. The two are often run together or cycled.

STUDIES

• Stroke recovery (2018, 110 patients). People recovering from ischaemic stroke were given Semax nasally in two 10-day courses. It raised blood levels of BDNF (a protein that supports nerve growth and repair), and they stayed high throughout the study. Semax and higher BDNF both sped up recovery and improved final scores on the Barthel index, a standard measure of everyday independence.
  • Movement scores (MRC motor scale) also improved over about five months, whether rehabilitation started early or late.
• Acute stroke (1997). An early clinical and EEG study compared 30 acute stroke patients on Semax with 80 control patients with strokes of similar severity and location.
• Chronic poor blood flow to the brain (2005). A Gusev-group study of 187 patients reported clinical improvement, slowed disease progression and lower stroke risk.

LINKS

• Gusev et al. 2018 – Semax in ischaemic stroke (PubMed)
• Gusev et al. 1997 – Semax in acute ischaemic stroke
• Superpower – Semax guide
• Superpower – Semax guide (2005 study and status)
• Wikipedia

Lyophilised powder